{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:11:27Z","timestamp":1770747087362,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41397-019-0111-3","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T14:57:51Z","timestamp":1571324271000},"page":"220-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure?"],"prefix":"10.1038","volume":"20","author":[{"given":"Ruben P. A.","family":"van Eijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinus J. C.","family":"Eijkemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Nikolakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc D.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk-Jan","family":"Westeneng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristel R.","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick A. A.","family":"van der Spek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joke J. F. A.","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanne","family":"Piepers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert-Jan","family":"Groeneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.","family":"Veldink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard H.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"van Es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"111_CR1","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","volume":"390","author":"MA van Es","year":"2017","unstructured":"van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084\u201398.","journal-title":"Lancet"},{"key":"111_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1212\/WNL.0000000000004606","volume":"89","author":"RPA van Eijk","year":"2017","unstructured":"van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89:1915\u201322.","journal-title":"Neurology"},{"key":"111_CR3","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1038\/550S120a","volume":"550","author":"A Scott","year":"2017","unstructured":"Scott A. Drug therapy: on the treatment trail for ALS. Nature. 2017;550:S120\u2013S121.","journal-title":"Nature"},{"key":"111_CR4","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1474-4422(14)70129-2","volume":"13","author":"H Mitsumoto","year":"2014","unstructured":"Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127\u201338.","journal-title":"Lancet Neurol"},{"key":"111_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/mus.24198","volume":"49","author":"XW Su","year":"2014","unstructured":"Su XW, Broach JR, Connor JR, Gerhard GS, Simmons Z. Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. Muscle Nerve. 2014;49:786\u2013803.","journal-title":"Muscle Nerve"},{"key":"111_CR6","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2018.6360","volume":"319","author":"K Broglio","year":"2018","unstructured":"Broglio K. Randomization in clinical trials: permuted blocks and stratification. JAMA. 2018;319:2223\u20134.","journal-title":"JAMA"},{"key":"111_CR7","doi-asserted-by":"crossref","unstructured":"Friedman LM, Furberg C, DeMets DL. Fundamentals of clinical trials, 4th edn. New York:Springer; 2010, xviii, p. 445.","DOI":"10.1007\/978-1-4419-1586-3"},{"key":"111_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/1740774510375455","volume":"7","author":"SJ Wang","year":"2010","unstructured":"Wang SJ, O'Neill RT, Hung HJ. Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials. Clin Trials. 2010;7:525\u201336.","journal-title":"Clin Trials"},{"key":"111_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435\u201342.","journal-title":"Lancet Neurol"},{"key":"111_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/17482968.2012.724074","volume":"14","author":"DJ Lange","year":"2013","unstructured":"Lange DJ, Andersen PM, Remanan R, Marklund S, Benjamin D. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:199\u2013204.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"111_CR11","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1212\/WNL.0000000000004960","volume":"90","author":"M Benatar","year":"2018","unstructured":"Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565\u2013e574.","journal-title":"Neurology"},{"key":"111_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ana.10554","volume":"53","author":"GJ Groeneveld","year":"2003","unstructured":"Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53:437\u201345.","journal-title":"Ann Neurol"},{"key":"111_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.21620","volume":"66","author":"S Piepers","year":"2009","unstructured":"Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol. 2009;66:227\u201334.","journal-title":"Ann Neurol"},{"key":"111_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1081\/BIP-120014565","volume":"12","author":"L Cui","year":"2002","unstructured":"Cui L, Hung HM, Wang SJ, Tsong Y. Issues related to subgroup analysis in clinical trials. J Biopharm Stat. 2002;12:347\u201358.","journal-title":"J Biopharm Stat"},{"key":"111_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/ng.442","volume":"41","author":"MA van Es","year":"2009","unstructured":"van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083\u20137.","journal-title":"Nat Genet"},{"key":"111_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245\u201356.","journal-title":"Neuron"},{"key":"111_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ng.3622","volume":"48","author":"W van Rheenen","year":"2016","unstructured":"van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48:1043\u20138.","journal-title":"Nat Genet"},{"key":"111_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/jnnp.2009.181453","volume":"81","author":"MA van Es","year":"2010","unstructured":"van Es MA, Dahlberg C, Birve A, Veldink JH, van den Berg LH, Andersen PM. Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:562\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"111_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/jmedgenet-2014-102360","volume":"51","author":"C Akimoto","year":"2014","unstructured":"Akimoto C, Volk AE, van Blitterswijk M, Van den Broeck M, Leblond CS, Lumbroso S, et al. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet. 2014;51:419\u201324.","journal-title":"J Med Genet"},{"key":"111_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/brain\/awr365","volume":"135","author":"J Cooper-Knock","year":"2012","unstructured":"Cooper-Knock J, Hewitt C, Highley JR, Brockington A, Milano A, Man S, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 2012;135:751\u201364.","journal-title":"Brain"},{"key":"111_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3109\/17482960802673042","volume":"10","author":"EsMA Van","year":"2009","unstructured":"Van EsMA, Van Vught PW, Veldink JH, Andersen PM, Birve A, Lemmens R, et al. Analysis of FGGY as a risk factor for sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:441\u20137.","journal-title":"Amyotroph Lateral Scler"},{"key":"111_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-139","volume":"15","author":"BC Kahan","year":"2014","unstructured":"Kahan BC, Jairath V, Dore CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014;15:139.","journal-title":"Trials"},{"key":"111_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","volume":"17","author":"HJ Westeneng","year":"2018","unstructured":"Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423\u201333.","journal-title":"Lancet Neurol"},{"key":"111_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/00031305.2012.671724","volume":"66","author":"RS Poulson","year":"2012","unstructured":"Poulson RS, Gadbury GL, Allison DB. Treatment heterogeneity and individual qualitative interaction. Am Stat. 2012;66:16\u201324.","journal-title":"Am Stat"},{"key":"111_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/brain\/awr366","volume":"135","author":"A Chio","year":"2012","unstructured":"Chio A, Borghero G, Restagno G, Mora G, Drepper C, Traynor BJ, et al. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain. 2012;135:784\u201393.","journal-title":"Brain"},{"key":"111_CR26","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown Jr.","year":"2017","unstructured":"Brown RH Jr., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377:1602.","journal-title":"N Engl J Med"},{"key":"111_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp-2017-317077","volume":"89","author":"RPA van Eijk","year":"2018","unstructured":"van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, van den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol, Neurosurg, psychiatry. 2018;89:156\u201361.","journal-title":"J Neurol, Neurosurg, psychiatry"},{"key":"111_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59\u201362.","journal-title":"Nature"},{"key":"111_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257\u201368.","journal-title":"Neuron"},{"key":"111_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neulet.2016.09.007","volume":"636","author":"X Wen","year":"2017","unstructured":"Wen X, Westergard T, Pasinelli P, Trotti D. Pathogenic determinants and mechanisms of ALS\/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene. Neurosci Lett. 2017;636:16\u201326.","journal-title":"Neurosci Lett"},{"key":"111_CR31","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1146\/annurev.neuro.27.070203.144244","volume":"27","author":"LI Bruijn","year":"2004","unstructured":"Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723\u201349.","journal-title":"Annu Rev Neurosci"},{"key":"111_CR32","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1093\/hmg\/ddt117","volume":"22","author":"C Vance","year":"2013","unstructured":"Vance C, Scotter EL, Nishimura AL, Troakes C, Mitchell JC, Kathe C, et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum Mol Genet. 2013;22:2676\u201388.","journal-title":"Hum Mol Genet"},{"key":"111_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000095110","volume":"28","author":"P Montague","year":"2006","unstructured":"Montague P, McCallion AS, Davies RW, Griffiths IR. Myelin-associated oligodendrocytic basic protein: a family of abundant CNS myelin proteins in search of a function. Dev Neurosci. 2006;28:479\u201387.","journal-title":"Dev Neurosci"},{"key":"111_CR34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2217\/pgs.12.10","volume":"13","author":"FH van der Baan","year":"2012","unstructured":"van der Baan FH, Knol MJ, Klungel OH, Egberts AC, Grobbee DE, Roes KC. Potential of adaptive clinical trial designs in pharmacogenetic research. Pharmacogenomics. 2012;13:571\u20138.","journal-title":"Pharmacogenomics"},{"key":"111_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jclinepi.2018.02.013","volume":"98","author":"RPA van Eijk","year":"2018","unstructured":"van Eijk RPA, Nikolakopoulos S, Ferguson TA, Liu D, Eijkemans MJC, van den Berg LH. Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs. J Clin Epidemiol. 2018;98:80\u20138.","journal-title":"J Clin Epidemiol"},{"key":"111_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0929-6646(09)60005-X","volume":"107","author":"SJ Wang","year":"2008","unstructured":"Wang SJ. Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program. J Formos Med Assoc. 2008;107:19\u201327.","journal-title":"J Formos Med Assoc"},{"key":"111_CR37","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1212\/01.wnl.0000299187.90432.3f","volume":"70","author":"A Chio","year":"2008","unstructured":"Chio A, Traynor BJ, Lombardo F, Fimognari M, Calvo A, Ghiglione P, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology. 2008;70:533\u20137.","journal-title":"Neurology"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0111-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0111-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0111-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:00:04Z","timestamp":1684616404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-019-0111-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1038\/s41397-019-0111-3","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RPAvE, SN, MDJ, H-JW, KRvE, RAAvdS, JJFAvV, SP, G-JG, JHV, MJCE report no disclosures. MAvE received grants from the Netherlands Organization for Health Research and Development (Veni scheme), The Thierry Latran foundation and the Netherlands ALS foundation (Stichting ALS Nederland), the EU Joint Programme\u2014Neurodegenerative Disease Research (JPND). LHvdB reports grants from Netherlands ALS Foundation, the Netherlands Organization for Health Research and Development (Vici scheme), the Netherlands Organization for Health Research and Development (SOPHIA, STRENGTH, ALS-CarE project), funded through the EU Joint Programme\u2014Neurodegenerative Disease Research, JPND), served on the Scientific Advisory Board of Biogen, Cytokinetics, Prinses Beatrix SpierFonds, and the Latran Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}